Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines

被引:2
|
作者
Breen, Laura [1 ]
Heenan, Mary [1 ]
Amberger-Murphy, Verena [1 ]
Clynes, Martin [1 ]
机构
[1] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland
关键词
p53; lung cancer; chemotherapy resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 is a tumour suppressor gene, which is mutated in more than half of all tumours. Most chemotherapeutic drugs cause DNA damage, which is sensed by p53; the cell can then try to repair the damage or induce cell suicide. If the p53 machinery is defective, effective chemotherapy is made more difficult. Materials and Methods: Wild-type p53 was transfected into lung cancer cell lines with different p53 status. The transfected cells were tested for changes in sensitivity to a range of chemotherapeutic agents. Results: We observed only modest changes in the sensitivity to the chemotherapeutic agents adriamycin, taxol and carboplatin in the transfected cells lines. p53 protein was detected in a transfected clone of the cell line H1299, whose parent cells are p53 null. However, the protein did not accumulate after DNA damage, suggesting that this cell line utilises alternative pathways for responding to stress, and no longer has a functional p53 pathway. Conclusion: The results suggest that introduction of wild-type p53 alone is not sufficient to substantially alter the sensitivity of a cell line to a given chemotherapeutic agent.
引用
收藏
页码:1361 / 1364
页数:4
相关论文
共 50 条
  • [11] p53 and lung cancer
    Brambilla, E
    Brambilla, C
    PATHOLOGIE BIOLOGIE, 1997, 45 (10): : 852 - 863
  • [12] Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    Antonia, SJ
    Mirza, N
    Fricke, I
    Chiappori, A
    Thompson, P
    Williams, N
    Bepler, G
    Simon, G
    Janssen, W
    Lee, JH
    Menander, K
    Chada, S
    Gabrilovich, DI
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 878 - 887
  • [13] p53 Mutation in Inflammatory Breast Cancer Cell Lines
    Li, C.
    Lee, B-N
    Woodward, W. A.
    Ueno, N. T.
    Robertson, F.
    Reuben, J. M.
    Cristofanilli, M.
    CANCER RESEARCH, 2009, 69 (24) : 699S - 700S
  • [14] MYC AND P53 ONCOGENE EXPRESSION IN HUMAN-LUNG CANCER CELL-LINES
    VINOCOUR, M
    MINNA, JD
    FEDERATION PROCEEDINGS, 1987, 46 (03) : 740 - 740
  • [15] p53 overexpression predicts the resistence to chemotherapy in non small cell lung cancer (NSCLC).
    Darwish, S
    Gregorc, V
    Pistola, L
    Ludovini, V
    De Angelis, V
    Cagini, L
    Tonato, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3743S - 3743S
  • [16] Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status
    Serafin, AM
    Akudugu, JM
    Bohm, L
    UROLOGICAL RESEARCH, 2002, 30 (05): : 289 - 294
  • [17] Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status
    Antonio M. Serafin
    John M. Akudugu
    Lothar Bohm
    Urological Research, 2002, 30 : 289 - 294
  • [18] Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines
    Duarte, Mariana Lemos
    de Moraes, Emanuela
    Pontes, Elizangela
    Schluckebier, Luciene
    de Moraes, Joyce Luana
    Hainaut, Pierre
    Ferreira, Carlos Gil
    CANCER LETTERS, 2009, 279 (01) : 57 - 64
  • [19] Prognostic role of serum p53 antibodies in lung cancer
    Manlio Mattioni
    Silvia Soddu
    Andrea Prodosmo
    Paolo Visca
    Salvatore Conti
    Gabriele Alessandrini
    Francesco Facciolo
    Lidia Strigari
    BMC Cancer, 15
  • [20] Prognostic role of serum p53 antibodies in lung cancer
    Mattioni, Manlio
    Soddu, Silvia
    Prodosmo, Andrea
    Visca, Paolo
    Conti, Salvatore
    Alessandrini, Gabriele
    Facciolo, Francesco
    Strigari, Lidia
    BMC CANCER, 2015, 15